IL-22 Antibody (142928)

Recombinant Human IL-22 (Catalog # 782-IL) stimulates IL‑10 secretion in the COLO 205 human colorectal adeno­carcinoma cell line in a dose-dependent manner (orange line), as measured by the Human IL‑10 DuoSet ELISA Development Kit (Catalog # DY217B). IL‑10 secretion elicited by Recombinant Human IL‑22 (1 ng/mL) is neutralized (green line) by increasing concentrations of Human IL‑22 Monoclonal Antibody (Catalog # MAB7821). The ND50 is typically 1-5 µg/mL.

• Reactivity: Hu
• Applications: B/N
• Clone: 142928
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Unconjugated

IL-22 Antibody (142928) Summary

• Immunogen: E. coli-derived recombinant human IL-22
  Ala34-Ile179
  Accession # Q9GZX6
• Specificity: Detects human IL-22 in direct ELISAs. In direct ELISAs, this antibody shows 100% cross-reactivity with recombinant mouse IL‑22 and recombinant rat IL‑22 and no cross-reactivity with recombinant human IL‑10.
• Source: N/A
• Isotype: IgG1
• Clonality: Monoclonal
• Host: Mouse
• Gene: IL22
• Purity Statement: Protein A or G purified from hybridoma culture supernatant
• Endotoxin Note: <0.10 EU per 1 μg of the antibody by the LAL method.

Applications/Dilutions

• Dilutions:
  • Neutralization 1-5 ug/mL

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Preservative: No Preservative
• Reconstitution Instructions: Reconstitute at 0.5 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for IL-22 Antibody (142928)

• Cytokine Zcyto18
• IL-10-related T-cell-derived inducible factor
• IL22
• IL-22
• IL-D110
• IL-TIF
• ILTIFIL-10-related T-cell-derived-inducible factor
• IL-TIFMGC79382
• interleukin 22
• interleukin-22
• MGC79384
• TIFa
• TIFIL-23
• zcyto18

Background

Interleukin-22 (IL-22), also known as IL-10-related T cell-derived inducible factor (IL-TIF) was initially identified as a gene induced by IL-9 in mouse T cells and mast cells. Human IL-22 cDNA encodes a 179 amino acid (aa) residue protein with a putative 33 aa signal peptide that is cleaved to generate a 147 aa mature protein that shares approximately 79% and 22% aa sequence identity with mouse IL-22 and human IL-10, respectively. The human IL-22 gene is localized to chromosome 12q15. Although it exists as a single copy gene in human and in many mouse strains, the mouse IL-22 gene is duplicated in some mouse strains including C57B1/6, FVB and 129. The two mouse genes designated IL-TIF alpha and IL-TIF beta , share greater than 98% sequence homology in their coding region. IL-22 has been shown to activate STAT1 and STAT3 in several hepatoma cell lines and upregulate the production of acute phase proteins. IL-22 is produced by normal T cells upon anti-CD3 stimulation in humans. Mouse IL-22 expression is also induced in various organs upon lipopolysaccharide injection, suggesting that IL-22 may be involved in inflammatory responses. The functional IL-22 receptor complex consists of two receptor subunits, IL-22 R (previously an orphan receptor named CRF2-9) and IL-10R beta (previously known as CRF2-4), belonging to the class II cytokine receptor family.

1. Dumoutier, L. et al. (2000) J. Immunol. 164:1814.
2. Xie, M-H. et al. (2000) J. Biol. Chem. 275:31335.
3. Dumoutier, L. et al. (2000) Proc. Natl. Acad. Sci. USA 97:10144.
4. Kotenko, S.V. et al. (2001) J. Biol. Chem. 276:2725.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for IL-22 Antibody (MAB7821)(6)

Publications using MAB7821

• J Chen, CA Haller, FE Jernigan, SK Koerner, DJ Wong, Y Wang, JE Cheong, R Kosaraju, J Kwan, DD Park, B Thomas, S Bhasin, RC De La Rosa, AM Premji, L Liu, E Park, AC Moss, A Emili, M Bhasin, L Sun, EL Chaikof Modulation of lymphocyte-mediated tissue repair by rational design of heterocyclic aryl hydrocarbon receptor agonists Sci Adv, 2020-01-15;6(3):eaay8230. 2020-01-15 [PMID: 31998845] (Flow Cytometry, Human)
• Xiaomeng Wang, Jiali Xu, Jin Chen, Shidai Jin, Jiaqi Yao, Tongfu Yu et al. IL-22 Confers EGFR-TKI Resistance in NSCLC via the AKT and ERK Signaling Pathways Frontiers in Oncology 11/5/2019 [PMID: 31750252]
• Zhang F, Shang D, Zhang Y, Tian Y Interleukin-22 suppresses the growth of A498 renal cell carcinoma cells via regulation of STAT1 pathway. PLoS ONE, 2011-05-23;6(5):e20382. 2011-05-23 [PMID: 21625390] (Neutralization, Human)
• Chang Y, Al-Alwan L, Risse PA, Roussel L, Rousseau S, Halayko AJ, Martin JG, Hamid Q, Eidelman DH TH17 cytokines induce human airway smooth muscle cell migration. J. Allergy Clin. Immunol., 2011-02-22;127(4):1046-53.e1-2. 2011-02-22 [PMID: 21345484] (Neutralization, Human)
• Res PC, Piskin G, de Boer OJ, van der Loos CM, Teeling P, Bos JD, Teunissen MB Overrepresentation of IL-17A and IL-22 producing CD8 T cells in lesional skin suggests their involvement in the pathogenesis of psoriasis. PLoS ONE, 2010-11-24;5(11):e14108. 2010-11-24 [PMID: 21124836] (IHC-P, Human)
• Pennino D, Eyerich K, Scarponi C, Carbone T, Eyerich S, Nasorri F, Garcovich S, Traidl-Hoffmann C, Albanesi C, Cavani A IL-17 amplifies human contact hypersensitivity by licensing hapten nonspecific Th1 cells to kill autologous keratinocytes. J. Immunol., 2010-03-31;184(9):4880-8. 2010-03-31 [PMID: 20357258] (Neutralization, Human)

Bioinformatics

• Gene Symbol: IL22
• Uniprot:
  • Q9GZX6()